Merck Nears Completion of Singapore Expansion

August 3, 2006
Patricia Van Arnum

Patricia Van Arnum was executive editor of Pharmaceutical Technology.

ePT--the Electronic Newsletter of Pharmaceutical Technology

MSD Technology Singapore Pte Ltd., a wholly owned subsidiary of Merck & Co., Inc. (Whitehouse Station, NJ) dedicated an expansion of its production facilities in Singapore on July 28.

MSD Technology Singapore Pte Ltd., a wholly owned subsidiary of Merck & Co., Inc. (Whitehouse Station, NJ, www.merck.com) dedicated an expansion of its production facilities in Singapore on July 28. The expanded facilities are scheduled to open in the fourth quarter of 2006.

Now in the final stages of construction, the expansion consists of manufacturing formulation facilities and support infrastructure, and will increase capacity and production capability at the 49-acre site in Tuas Biomedical Park. The new SGD 100-million ($63 million) project brings Merck's overall investment in Singapore to more than SGD $1 billion ($633 million).

The expansion shares its Tuas Biomedical Park site with a bulk-pharmaceutical plant, which MSD opened in September 2001, and a formulation facility with more than 15,000 m2 of floor space, which opened in October 2003.

Related Content:

PharmTech News | Manufacturing